In anterior cruciate ligament reconstruction and rotator cuff repair, PURASORB PLDL 7038 is converted into fully resorbable interference screws and suture anchors by medical-grade injection moulding. The resin is a 70:30 L-lactide/DL-lactide copolymer with nominal inherent viscosity of 3.8 dL/g measured in chloroform at 25 °C and 0.1 g/dL. The relevant standards matrix comprises ISO 13781:2017 for lactide copolymers intended for surgical implants, ASTM F2502-17 for absorbable plates and screws, ISO 10993-5:2009, ISO 10993-10:2010, and ISO 10993-11:2017 under the risk-management framework of ISO 10993-1:2018. Where an osteoconductive interference-screw variant is specified, β-tricalcium phosphate is melt-compounded with PLDL 7038 at addition ratios of 10 wt% to 30 wt%; unfilled screws and anchors use the polymer at 100 wt% with no plasticiser or organic solvent content. Granule drying at 60 °C under vacuum to residual moisture below 0.01 wt% precedes melt conversion to suppress hydrolytic chain scission. Compounding is performed on a co-rotating twin-screw extruder with 32:1 L/D, barrel temperature from 170 °C to 195 °C, screw speed 80–120 rpm, and melt residence time below 8 min. Injection moulding of the compounded resin into single-cavity surgical tooling uses melt temperature 180–200 °C, mould temperature 25–40 °C, injection speed controlled to avoid shear-induced crystallisation at flow restrictions below 1.5 mm, and holding pressure limited to 700–900 bar to reduce orientation and gate stress. After ejection, sprues and gate vestiges are removed by cryogenic trimming or oil-free clean-room machining. Terminal device types include tibial and femoral interference screws from 6 mm to 12 mm outside diameter, knotless suture anchors with eyelet diameters from 1.9 mm to 3.5 mm, and screw-and-sheath fixation systems for ligament reconstruction.

What Processing Boundaries Govern Craniomaxillofacial Fixation Mesh and Plate Forming?

Craniomaxillofacial osteosynthesis devices from PLDL 7038 are produced by vacuum compression and thermoforming routes rather than by machining sterile block stock. The accepted compliance pathway includes ISO 10993-1:2018, chemical characterisation per ISO 10993-18:2020, cytotoxicity per ISO 10993-5:2009, implantation testing per ISO 10993-6:2016, and material specification under ASTM F1925-22 for semi-crystalline lactide copolymers compared against lot-based degradation profiles. Addition ratios in compression-moulded mesh and plate precursors are typically 100 wt% PLDL 7038 for radiolucent devices; if intraoperative radiopacity is required, barium sulfate or β-tricalcium phosphate is limited to 5–15 wt% because higher filler fractions reduce notched impact resistance and create micro-crack initiation sites at screw-hole stress risers. Dried granules are pressed into sheet under vacuum in a heated hydraulic platen press with 300–500 kN capacity at 180–195 °C, then cooled from 120 °C to 40 °C at ≤2 °C/min to stabilise crystallite dimensions. Post-forming annealing at 90–110 °C for 4–8 h reduces residual stress around cut screw holes; thermoforming is conducted on patient-specific or size-specific tooling under controlled sheet reheat below 120 °C. Finished device configurations include resorbable maxillofacial plates with thickness from 0.8 mm to 2.0 mm, orbital floor sheets with preformed curvature, and low-profile craniofacial fixation mesh suitable for periosteal placement. These devices are double-pouch packaged and sterilised by ethylene oxide according to ISO 11135:2014, with packaging validation under ISO 11607-1:2019.

Radial strength retention beyond 6 months before significant mass loss is the primary driver for extrusion of PLDL 7038 into fully bioresorbable vascular scaffold tubes. Hemocompatibility and implant safety for this vascular application are governed by ISO 10993-4:2017, ISO 10993-6:2016, and endovascular device performance under ISO 25539-1:2017; degradation product identification is addressed by ISO 10993-13:2010. The addition ratio in the load-bearing strut core is 100 wt% PLDL 7038; if an antiproliferative topcoat is applied, the drug-polymer layer is a separate lower-viscosity lactide-glycolide copolymer deposited at 5–12 μm thickness and is not blended into the structural melt. Tube extrusion uses a single-screw extruder with 25:1 L/D, melt filtration through 20 μm sintered-metal screen packs, gear-pump-controlled throughput, and precision air-bearing die gaps to maintain wall-thickness tolerance below ±5 % of nominal. The extruded tube is laser-cut with a 1064 nm femtosecond or nanosecond system, cleaned to remove ablation debris, then expanded at 45–65 °C to orient strut chains and increase radial stiffness without inducing crystallite fracture. Additional processing includes crimping onto balloon delivery catheters, ethylene oxide sterilisation, and barrier packaging under ISO 11607-1:2019. Terminal finished product types include fully bioresorbable vascular scaffolds for coronary and peripheral segments, paediatric resorbable stents where permanent metallic cages are contraindicated, and semi-finished structural stent tubes supplied for coating and final assembly.

Table 1 consolidates the primary compliance test matrix for the above PLDL 7038 device categories.

When a 70:30 L-lactide/DL-lactide Copolymer Is Electrospun into Barrier Membranes

When a 70:30 L-lactide/DL-lactide copolymer is electrospun into barrier membranes for alveolar ridge preservation, PLDL 7038 is processed as a solvent-based formulation rather than a melt. Compliance for these wound-contacting devices is anchored by ISO 10993-1:2018, cytotoxicity per ISO 10993-5:2009, sensitisation per ISO 10993-10:2010, and systemic toxicity per ISO 10993-11:2017; scaffold characterisation follows ASTM F2150-19 for fibre diameter distribution, pore size, and interconnectivity. The addition ratio of PLDL 7038 in the electrospinning solution is typically 5–12 wt% in chloroform/N,N-dimethylformamide at 70:30 v/v, with solution conductivity adjusted to 1.5–4.0 μS/cm through solvent ratio rather than through salt addition; if nanohydroxyapatite is incorporated as a cell-instructive phase, it is added at 5–10 wt% of polymer mass and dispersed by ultrasonic homogenisation before spinning. The solution is delivered through a 21 G blunt-tip needle at 0.3–1.2 mL/h under direct-current voltage of 15–25 kV and collector distance 12–18 cm. Deposition occurs onto a rotating drum collector at 0.5–2.0 m/s to orient fibres and improve tensile resistance parallel to the long alveolar axis. Residual solvent is removed by vacuum extraction at 45 °C for 48–72 h until chloroform concentration is below 50 ppm; amine-based salt additives must be excluded because residual amines accelerate lactide ester hydrolysis and create inconsistent degradation profiles. Released product forms include single-layer barrier membranes with thickness from 200 μm to 500 μm, hydroxyapatite-reinforced composite membranes, and pre-shaped dentoalveolar tenting membranes for socket preservation and sinus floor coverage. Gamma sterilisation above 25 kGy may shift molecular weight distribution unless oxygen- and moisture-barrier packaging is used; ethylene oxide is therefore the preferred terminal sterilisation mode unless radiation validation is performed.

Melt-spun monofilament drawing and suture mechanical performance

Melt-spun monofilament drawing and suture mechanical performance require a thermal history distinct from injection-moulded PLDL 7038 parts. Suture-grade monofilament is produced by ram extrusion or melt spinning of dried granules under nitrogen purge to reduce oxidative discolouration. The applicable test regime includes USP <87> and USP <88> Class VI biological reactivity, ISO 10993-6:2016 for local tissue reaction, ISO 13781:2017 for lactide copolymer identity and degradation requirements, and tensile evaluation under ASTM D2256-21 for research comparisons together with pharmacopoeial monograph release testing for finished suture lots. The formulation addition ratio is 100 wt% PLDL 7038; if a non-cytotoxic pigment is needed for suture-size identification, it is added at ≤0.1 wt% and must pass ISO 10993-5:2009 extraction testing before lot approval. Melt spinning is performed through a 1.0–2.5 mm spinneret at 180–200 °C, followed by two-stage drawing: first draw ratio 2.5:1–3.5:1 at 60–80 °C, second draw ratio 1.5:1–2.0:1 at 90–110 °C, and constrained annealing at 100–120 °C for 6–12 h to reduce free shrinkage below 2 %. Terminal finished product types include monofilament sutures in USP sizes 6-0 through 2, knitted resorbable mesh for anterior abdominal wall repair, and oriented fibre bundles for ligament augmentation devices. Moisture exposure during spinning must be kept below 0.01 wt% because hydrolytic scission reduces drawability and knot-pull reproducibility across production batches.

Used as filament feedstock for fused filament fabrication, PLDL 7038 supports patient-specific absorbable scaffolds when extruded into filament without plasticiser or filler. The quality system and device evaluation pathway combines ISO 13485:2016, ISO 10993-1:2018, ISO 10993-5:2009, and process validation under ISO/ASTM 52900:2021; if the printed scaffold is intended for bone regeneration, ASTM F2150-19 is also used to document pore size distribution and interconnectivity. The addition ratio in filament feedstock is 100 wt% PLDL 7038, with moisture control rather than chemical modification as the main process adjustment; granule drying at 60 °C to below 0.01 wt% residual moisture precedes filament extrusion. Filament is produced on a single-screw extruder with 25:1 L/D, melt temperature 180–200 °C, water quenching at 20–30 °C, and diameter controlled to 1.75 mm ±0.05 mm by laser gauging and closed-loop spool speed. Printing is conducted at nozzle temperatures of 190–215 °C, bed temperature 55–65 °C, layer height 0.1–0.2 mm, and print speed 20–40 mm/s to reduce die swell and interlayer void formation; after printing, parts are annealed at 80–100 °C under nitrogen and cleaned of support material by low-temperature mechanical deboss or ultrasonic washing in isopropanol. Published device-specific mechanical data for PLDL 7038 printed scaffolds is limited; the processing bounds above are derived from semi-crystalline 70:30 L-lactide/DL-lactide copolymer filament extrusion parameters and must be verified against lot-specific molecular weight distribution. Validated terminal product forms include patient-specific craniofacial bone scaffolds, orbital reconstruction templates, and custom bone void fillers produced under hospital printer validation according to anatomical segmentation data.